VTv Therapeutics Shares Rise After FDA Lifts Hold on Diabetes Treatment

Dow Jones
03-17

By Katherine Hamilton

Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program.

The stock gained 40% to $20.78 Monday morning. Shares have climbed almost 50% in 2025.

The High Point, N.C., biopharmaceutical company said Monday it expects to resume its cadisegliatin clinical program, including a Phase 3 trial in type 1 diabetes. The FDA had placed a hold on the trial after discovering a chromatographic signal in a human absorption, distribution, metabolism and excretion study of cadisegliatin.

VTv submitted a response letter concluding that the chromatographic signal was an experimental artifact and the FDA lifted the hold Friday.

Before resuming the trial, vTv plans to submit a protocol amendment to reduce the overall duration of the trial to six months from 12 months to expedite the initiation of required larger pivotal studies for future New Drug Application submissions. By shortening the trial, vTv can collect topline data from the study more quickly, it said. The planned change will not include the additional six-month period to collect safety data, vTv said.

Cadisegliatin is an oral, liver selective glucokinase activator that's being investigated as an adjunctive treatment to insulin for type 1 diabetes. The company announced the Phase 3 trial in July. No patient had been dosed at the time of the clinical hold and past clinical studies did not reveal any concerning safety issues, vTv said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

 

(END) Dow Jones Newswires

March 17, 2025 11:01 ET (15:01 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10